- Home
- PLRX vs INMB Comparison
PLRX vs INMB Comparison
Compare PLRX & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLRX | INMB |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.6M | 57.9M |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PLRX | INMB |
|---|---|---|
| Price | $1.07 | $2.17 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 5 |
| Target Price | $2.67 | ★ $5.40 |
| AVG Volume (30 Days) | ★ 407.4K | 354.0K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.97 | 11.85 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $50,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 257.14 |
| 52 Week Low | $1.02 | $1.09 |
| 52 Week High | $1.95 | $2.58 |
Technical Indicators
Market Signals| Indicator | PLRX | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 47.40 | 65.83 |
| Support Level | N/A | $1.37 |
| Resistance Level | $1.27 | $2.17 |
| Average True Range (ATR) | 0.03 | 0.12 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 62.50 | 88.89 |
Price Performance
Historical ComparisonAbout PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
About INMB INmune Bio Inc.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.